Decoding real-world outcomes: exploring clinical features associated with efficacy in patients treated with dupilumab. Mendeley Supplements.

1. Supplemental Materials including:
Supplemental Table 1: Patients’ demographics and baseline disease characteristics.
Supplemental Table 2: Patient-reported outcomes with treatment of dupilumab in 16 weeks among different age groups.
Supplemental Table 3: Associations between patients’ characteristics and EASI-75 at week 16 among different age groups.
Supplemental Table 4: Adverse events while on dupilumab therapy among different groups.
Supplementary Figure 1: Graphical abstract.
Supplementary Figure 2: Predictability of week 16 EASI-75 responses by PP-NRS change from baseline at week 2 with dupilumab.
2.Supplemental Methods